Latest Breaking News On - Early access program - Page 10 : comparemela.com

PROTEONIC UNVEILS EARLY ACCESS PROGRAM, ELEVATING VIRAL VECTOR TITERS WITH TRANSFORMATIVE LV-2G UNIC® TECHNOLOGY

PROTEONIC UNVEILS EARLY ACCESS PROGRAM, ELEVATING VIRAL VECTOR TITERS WITH TRANSFORMATIVE LV-2G UNIC® TECHNOLOGY
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJonathan framptonDennis riedlFrank pieperPrnewswire proteonic biosciencesBusiness developmentEarly access programNic biosciencesEarly accessDual promoter

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through AmpligenOCALA, Fla., March 25, 2024 AIM ImmunoTech Inc. today announced the.

United statesThomask equelsExchange commissionImmunotech incErasmus university medical centerEarly access programClinical cancer researchAdvanced pancreatic cancerAnti tumor immunityDendritic cell mediatedt responsesExecutive officer thomasPancreato biliary surgeonPrivate securities litigation reform act

MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference

LYON, France, March 12, 2024 Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, will present extended results from its Early Access Program for patients with aGvHD that were treated with MaaT013 and, for the first time, Overall Survival data after 12 months in more patients. The data will be shared during an oral p

United statesGlasgow cityUnited kingdomAlexander schauwvliegheMichael loschiEarly access programCorporate communicationsAmerican society of hematologyMeeting of the european society for bloodTrophic communicationsSenior pr corporate communicationsGraft vs host diseaseMaat pharmaRegulatory newsMicrobiome ecosystemOverall survival

GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024

PARIS (BUSINESS WIRE) Mar 12, 2024

United kingdomFrance generalUnited statesGuillaume van renterghemGensight biologics euronextLaurence rodriguezNancyj newmanIvan tortetGensight biologicsEuropean medicines agencyEmory university school of medicineOphthalmology societyEarly access programThree new meta analysesBusiness wireSight biologics

MaaT Pharma : Inside Information / Other news releases -March 12, 2024 at 04:46 am EDT

Press release MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference .

Alexander schauwvliegheSenior pr corporate communicationsTrophic communicationsEarly access program in europeOral presentationRefractory gastrointestinalEarly access programMaat pharmaMicrobiome ecosystem therapiesEuronext parisInvestor relations